The treatment of HIV-1 in people with antiretroviral resistance is challenging and costly. In addition to increased toxicity, potential for drug–drug interactions, and pill burden, the mean cost of antiretroviral therapy (ART) increases with each antiretroviral class to which a patient’s virus is resistant.1 The prevalence of transmission of any drug resistance in high-income countries, such as those in North America